GTG Labs (GENE): חובות להיוון בספרים

This debt-to-market cap chart illustrates the scaling potential of Genetic Technologies (GENE) through the global licensing of proprietary diagnostic methodologies. Meanwhile, 0.48 captures the magnitude of this parameter, accounting for a moderate dependence on external IT providers and logistics firms. However, the small size of the business creates risks of losing market share under pressure from industry behemoths in the oncology screening segment.

Genetic Technologies is actively expanding the presence of geneType IT tests within the B2B clinic segment. GURU.Markets tools allow for tracking the dynamics of the debt-to-capitalization ratio during this process. This metric compares total debt with the book value of assets to evaluate the financing structure. A decrease in the ratio minimizes credit risks, whereas excess equity may indicate an underutilization of leverage. This determines financial stability during business expansion.